Bausch Health Companies Inc.

BHC-T

TSE:BHC

38.81
0.00 (0.00%)
Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Canada.
More at Wikipedia

Analysis and Opinions about BHC-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
January 17, 2020
He gives managements kudos for restructuring the business. They are still heavily indebted. He is looking for valuation with consistent cashflow which this is not. It's not the type of company he looks at.
Show full opinionHide full opinion
He gives managements kudos for restructuring the business. They are still heavily indebted. He is looking for valuation with consistent cashflow which this is not. It's not the type of company he looks at.
WATCH
WATCH
November 19, 2019
Kudos to the management for selling off businesses and paying down debt. It may be something investor should look at again.
Show full opinionHide full opinion
Kudos to the management for selling off businesses and paying down debt. It may be something investor should look at again.
BUY
BUY
November 8, 2019
If it can continue on volume, it looks very positive. It has built a nice base and it’s worthy of a buy. Support should be around $27. He would aim for the 100 day moving average.
Show full opinionHide full opinion
If it can continue on volume, it looks very positive. It has built a nice base and it’s worthy of a buy. Support should be around $27. He would aim for the 100 day moving average.
BUY
BUY
November 4, 2019
A covered call He likes covered calls and you can do it with BHC. Write them and take the premium here. BHC has been rangebound, but demographics favour health stocks. However, governments will limit pricing of health services.
Show full opinionHide full opinion
A covered call He likes covered calls and you can do it with BHC. Write them and take the premium here. BHC has been rangebound, but demographics favour health stocks. However, governments will limit pricing of health services.
DON'T BUY
DON'T BUY
October 8, 2019
There's too much debt and not enough growth to pay it off. The stock has sold off as their generic products face new competition.
Show full opinionHide full opinion
There's too much debt and not enough growth to pay it off. The stock has sold off as their generic products face new competition.
COMMENT
COMMENT
August 2, 2019
They still only have a couple products that are growing. Other drugs are in their infancy or not growing. If they're not able to cover debt with free cashflow, you won't see any dividends.
Show full opinionHide full opinion
They still only have a couple products that are growing. Other drugs are in their infancy or not growing. If they're not able to cover debt with free cashflow, you won't see any dividends.
BUY
BUY
July 11, 2019
After a stunning fall from grace, there's been a stunning recovery. FMV is 127% higher than it's currently trading, and it's been there before. Looks like a resurrection.
Show full opinionHide full opinion
After a stunning fall from grace, there's been a stunning recovery. FMV is 127% higher than it's currently trading, and it's been there before. Looks like a resurrection.
DON'T BUY
DON'T BUY
May 2, 2019
There are better opportunities out there. They meet his criteria except for their debt levels.
Show full opinionHide full opinion
There are better opportunities out there. They meet his criteria except for their debt levels.
TOP PICK
TOP PICK
November 30, 2018
He likes it because nobody likes it. It is former Valiant Pharmaceuticals and trades at 6 times cash-flow. He encourages investors to look beyond its checkered past. It has high quality recurring cash-flows in the contact lens division. Every division is growing organically. It does have a high debt load, but the trajectory of cash flow will elevate that risk. Yield 0%. (Analysts’ price target is $35.39)
Show full opinionHide full opinion
He likes it because nobody likes it. It is former Valiant Pharmaceuticals and trades at 6 times cash-flow. He encourages investors to look beyond its checkered past. It has high quality recurring cash-flows in the contact lens division. Every division is growing organically. It does have a high debt load, but the trajectory of cash flow will elevate that risk. Yield 0%. (Analysts’ price target is $35.39)
COMMENT
COMMENT
October 17, 2018

It's the old Valeant. It has a future, cleaned up their act, but too much debt. Stable now, so maybe good for the long-term, certainly better than the Valeant days.

Show full opinionHide full opinion

It's the old Valeant. It has a future, cleaned up their act, but too much debt. Stable now, so maybe good for the long-term, certainly better than the Valeant days.

Showing 1 to 10 of 10 entries
  • «
  • 1
  • »